tepotinib

Drug Overview

Tepotinib is a highly specialized cancer medication. It is known as a Targeted Therapy or a “Smart Drug.” Unlike older chemotherapy treatments that attack all fast-growing cells in the body, targeted therapies are designed to find and attack specific parts of cancer cells. This helps to stop the cancer from growing while trying to limit the damage to healthy cells.

Here are the key details about this medication:

• Generic Name: tepotinib
• US Brand Names: Tepmetko
• Drug Class: Kinase Inhibitor (Oral MET Inhibitor)
• Route of Administration: Oral (taken by mouth as a tablet)
• FDA Approval Status: Yes. It was first granted accelerated approval by the US Food and Drug Administration (FDA) in February 2021. It received full, traditional FDA approval in February 2024.

What Is It and How Does It Work? (Mechanism of Action)

To understand how tepotinib works, it helps to look at how cells communicate. In our bodies, cells have special proteins on their surfaces called receptors. These receptors act like antennas, receiving signals that tell the cell to grow, divide, or stay alive.

One of these antennas is called the MET receptor. In some lung cancers, there is a mistake or “mutation” in the DNA that controls this receptor. This specific mistake is called a “MET exon 14 skipping alteration.” Because of this mistake, the MET receptor gets stuck in the “on” position. It constantly sends signals telling the cancer cells to multiply rapidly and spread to other parts of the body.

Tepotinib is a type of drug called a kinase inhibitor. It works on a molecular level to block these broken signals. When a patient takes tepotinib, the medicine travels through the bloodstream and finds the overactive MET receptors on the cancer cells. It binds tightly to these receptors and turns them “off.” By blocking these signals, tepotinib stops the cancer cells from growing and causes them to die off.

FDA Approved Clinical Indications

Currently, tepotinib is specifically approved for particular types of cancer. It is not used for all patients, but only for those whose tumors have specific genetic markers.

Oncological Uses:

• Metastatic Non-Small Cell Lung Cancer (NSCLC): Tepotinib is approved to treat adult patients with non-small cell lung cancer that has spread to other parts of the body (metastatic).
• The cancer must have the specific genetic mutation known as the mesenchymal-epithelial transition (MET) exon 14 skipping alteration. A special FDA-approved test is used to confirm if the tumor has this mutation before starting the drug.

Non-oncological Uses:

• There are currently no FDA-approved non-oncological uses for tepotinib.

Dosage and Administration Protocols

Because tepotinib is a powerful targeted therapy, taking the correct dose is very important for it to work well and to keep side effects manageable. Below is the standard protocol for taking this medication.

Note: Tablets should be swallowed whole. Do not chew, crush, or split them. For patients who have trouble swallowing, the tablets can be dropped into a small glass of water (30 mL), stirred until broken into small pieces, and swallowed immediately.

Clinical Efficacy and Research Results

Tepotinib has been carefully studied to see how well it helps lung cancer patients. The most important information comes from a large, international study called the VISION trial, which gathered data from 2020 through 2025.

The VISION trial looked at hundreds of patients with advanced non-small cell lung cancer that had the MET exon 14 skipping mutation. The results showed that tepotinib is highly effective:

• Tumor Shrinkage (Response Rate): For patients who had never received any cancer treatment before, 57% saw their tumors shrink significantly. For patients who had already tried other treatments (like chemotherapy), 45% saw their tumors shrink.
• Lasting Results: When the medicine worked, it kept working for a long time. Among the patients whose tumors shrank, about 40% continued to see benefits for 12 months or longer.
• Controlling the Disease: The time before the cancer started growing again (known as progression-free survival) averaged around 8 to 11 months.
• Overall Survival: Recent real-world data and long-term trial updates show that many patients live significantly longer on this treatment. In some study groups, the median overall survival reached up to 24 months, which is a major improvement for this specific type of advanced lung cancer.

Safety Profile and Side Effects

Like all cancer medicines, tepotinib can cause side effects. Because it is a targeted therapy, its side effects are different from standard chemotherapy.

Common Side Effects (>10%)

Many patients will experience mild to moderate side effects. The most common ones include:

• Edema (Swelling): Swelling in the hands, arms, legs, or feet is the most common side effect, affecting up to 81% of patients.
• Stomach Issues: Nausea (about 31%), diarrhea, and a loss of appetite.
• Fatigue: Feeling unusually tired or weak.
• Pain: Muscle and joint pain.
• Breathing Issues: Shortness of breath (dyspnea).
• Lab Changes: Increases in blood creatinine levels, which relate to how the kidneys are filtering.

Serious Adverse Events

Some side effects are rare but very serious. Patients are monitored closely for the following:

• Interstitial Lung Disease (ILD) / Pneumonitis: This is a severe inflammation of the lungs that can make it very hard to breathe. It can be life-threatening.
• Hepatotoxicity (Liver Damage): The drug can cause liver enzymes to rise, which is a sign of liver stress or damage.
• Embryo-Fetal Toxicity: This medicine can cause severe harm to an unborn baby.

Management Strategies

• For Swelling: Doctors may suggest keeping your legs elevated when sitting and wearing compression stockings.
• For Liver Health: Your medical team will run blood tests every two weeks for the first three months to check your liver. If your liver numbers go too high, your doctor will ask you to stop taking the drug until your liver heals, and then may restart it at a lower dose.
• For Lung Issues: If you suddenly develop a new cough, fever, or worse shortness of breath, contact your doctor immediately. If ILD is confirmed, you must permanently stop taking tepotinib.

Research Areas

While tepotinib is not directly combined with stem cell or regenerative medicine therapies at this time, there is exciting ongoing research into how it can be used with other modern treatments. Currently, scientists are studying how tepotinib might work alongside Immunotherapy (drugs like immune checkpoint inhibitors). Researchers are looking at clinical data to see if using tepotinib before or after immunotherapy can further extend the lives of patients with the MET exon 14 skipping mutation. They are also researching how cancer cells eventually learn to “outsmart” tepotinib, hoping to design new combination therapies to block the cancer from returning in the future.

Patient Management and Practical Recommendations

To get the best results and stay safe while taking tepotinib, patients and their healthcare providers must work together closely.

Pre-Treatment Tests to be Performed

Before starting this medication, your doctor will order several tests:

• Genetic Testing: A tissue biopsy or a liquid biopsy (blood test) to confirm your tumor has the MET exon 14 skipping mutation.
• Liver Function Tests: Blood tests to ensure your liver is healthy enough to process the medication.
• Pregnancy Test: A test for females of childbearing age to ensure they are not pregnant.

Precautions During Treatment

• Birth Control: Because of the risk to unborn babies, both men and women who are able to have children must use highly effective birth control during treatment and for at least one week after the last dose.
• Watch for Lung Changes: Pay very close attention to any changes in your breathing, such as a new or worsening cough.

“Do’s and Don’ts” List

• DO take your medicine at the same time every day.
• DO take your pills with a meal or a snack.
• DO call your doctor right away if you notice sudden swelling in your legs, a new cough, or yellowing of your eyes and skin.
• DON’T crush, chew, or split the tablets.
• DON’T take a missed dose if it is within 8 hours of your next scheduled dose. Just skip it and take your next dose on time.
• DON’T get pregnant or breastfeed while taking this medication.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Tepotinib is a prescription medication approved by the US Food and Drug Administration (FDA) for specific clinical indications. Every patient’s medical situation is unique. Always consult with a qualified healthcare professional or your treating oncologist regarding your diagnosis, treatment options, potential side effects, and whether this medication is appropriate for you.